Subtenon triamcinolone injection to treat serous choroidal detachment after glaucoma surgery: A case series

Eur J Ophthalmol. 2023 Jan;33(1):319-323. doi: 10.1177/11206721221108253. Epub 2022 Jun 13.

Abstract

Purpose: To report the effect of subtenon triamcinolone acetonide (TA) injection in the treatment of serous choroidal detachment (SCD) after glaucoma surgery.

Methods: In this prospective case series, patients with persistent, non-resolving, or progressive SCD after glaucoma surgery were enrolled. For those with non-resolving or progressive SCD despite of using systemic corticosteroids, topical atropine and topical steroids, one milliliter of TA (40mg/mL) was injected inferotemporally into the posterior subtenon space.

Results: Sixteen consecutive patients with a mean ± SD age of 70.12 ± 11.12 years were included in this study. After injection of subtenon TA, SCD was completely resolved after 1 to 4 weeks, with deepening of the anterior chamber in all cases. All cases were followed for at least 6 months after the injection with no signs of recurrence.

Conclusion: Subtenon injection of TA is a safe and effective modality of treatment for resolving a persistent or progressive SCD after glaucoma surgeries.

Keywords: Glaucoma surgery; choroidal detachment; triamcinolone acetonide.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Choroidal Effusions*
  • Glaucoma* / drug therapy
  • Glaucoma* / surgery
  • Glucocorticoids
  • Humans
  • Injections
  • Middle Aged
  • Vitrectomy

Substances

  • Glucocorticoids